Form 4: Glaukos CEO Earns Performance-Based Equity

Glaukos Corporation's Chairman and CEO, Thomas William Burns, acquired significant shares and stock options following the achievement of pre-determined operational targets.

Summary

• Thomas William Burns, Chairman and CEO of Glaukos Corp, acquired 9,380 shares of common stock from a March 24, 2022 restricted stock unit (RSU) award, with vesting contingent on operational targets achieved as determined on March 25, 2026.
• An additional 14,184 shares of common stock were acquired from a March 14, 2024 RSU award, also due to the achievement of operational targets determined on March 25, 2026.
• Burns also acquired 18,933 stock options from a March 24, 2022 award and 110,254 stock options from a March 22, 2023 award, both vesting upon the achievement of operational targets.
• A new grant of 98,474 stock options was made on March 25, 2026, with a four-year vesting schedule.
• Following these transactions, Burns directly beneficially owns 263,271 shares of common stock and indirectly owns 1,489,392 shares through various trusts.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively as it confirms the achievement of operational targets, leading to executive equity vesting, and includes a new long-term incentive grant, signaling confidence in future performance.

Positives

• The vesting of restricted stock units and stock options indicates the achievement of pre-determined operational targets by Glaukos Corporation.
• The Compensation, Nominating and Governance Committee determined on March 25, 2026, that certain operational targets were met, leading to the earning of these equity awards.
• A new stock option grant to the CEO aligns management incentives with long-term company performance.

Future Outlook

The vesting schedules for the acquired equity awards and the new option grant extend into future periods, indicating a long-term incentive structure tied to continued company performance.

Industry Context

StockSavvy.ai notes that performance-based equity awards are a common practice in the medical technology and ophthalmology industry, aligning executive incentives with shareholder value creation and operational success. The achievement of operational targets by Glaukos suggests strong execution within its competitive landscape.

Stakeholder Impact

• Shareholders: The achievement of operational targets and the alignment of executive incentives through equity awards could be viewed positively, suggesting strong company performance and management commitment.
• Employees: While not directly mentioned, successful achievement of operational targets can positively impact employee morale and potentially future compensation programs.

Next Steps

• Delivery of 50% of shares from the March 24, 2022 RSU award in March 2026.
• Delivery of 100% of shares from the March 14, 2024 RSU award in March 2026.
• Vesting and exercisability of 50% of options from the March 24, 2022 option award in March 2026.
• Delivery of the remaining 50% of shares from the March 24, 2022 RSU award in December 2026.
• Vesting and exercisability of the remaining 50% of options from the March 24, 2022 option award in December 2026.
• The new stock option granted on March 25, 2026, will vest 25% on its first anniversary (March 25, 2027) and the remainder in equal monthly installments for 36 months thereafter.

Key Dates

Recommendation

The filing indicates positive operational performance leading to executive equity vesting, which is a good sign. However, as a Form 4, it primarily reports compensation events rather than new strategic or financial disclosures that would warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for investors already in GKOS, suggesting continued stability and execution.

Keywords

Glaukos, GKOS, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Performance Targets, Thomas William Burns, Beneficial Ownership